Indiana University Foundation, Inc.

Researchers demonstrated for the first time that alternate-day fasting increases the efficacy of anti-androgen therapy in prostate cancer through preclinical mouse models.

A Swedish population study of 247,420 individuals found that ADHD medications consistently reduced risks of self-harm, unintentional injury, traffic crashes, and crime across all age groups and sexes.

The 62nd European Renal Association Congress in Vienna will present seven late-breaking clinical trials addressing chronic kidney disease, dialysis patients, and glomerular disease developments.

City of Hope has initiated a phase 1/2 clinical trial investigating whether denosumab, an FDA-approved osteoporosis medication, can protect and regenerate insulin-producing beta cells in early-stage type 1 diabetes patients.

Recent clinical trials demonstrate promising results for pembrolizumab plus lenvatinib combination in advanced B3-thymoma and thymic carcinoma, achieving an 88.4% progression-free survival rate at 5 months.

A clinical trial of 135 participants at Indiana University demonstrated that Syrenity app users showed positive trends in reducing depression symptoms compared to non-users over a six-week period.

New research reveals patients experiencing neuropathy, skin rash, or hyperglycemia while taking Enfortumab Vedotin showed significantly improved progression-free survival in metastatic urothelial carcinoma treatment.

A new study reveals that malaria parasites in African children are showing resistance to artemisinin, a key drug used to treat the disease.

• Real-world data from 72 MASH patients prescribed resmetirom show clinical characteristics and noninvasive test results consistent with phase 3 trial data. • The study, conducted across two US tertiary care centers, suggests resmetirom's effectiveness in clinical practice mirrors its performance in controlled trials. • Findings indicate appropriate patient selection for resmetirom can be achieved using noninvasive testing, potentially negating the need for liver biopsies. • The data offers a promising glimpse into resmetirom's utility in routine clinical settings, with ongoing data collection aimed at further validating its real-world efficacy.